Mammalian checkpoint kinases 1 and 2 (Chk1 and Chk2) are essential kinases that are involved in cell cycle checkpoint control, and the abrogation of either has been proposed as one way to sensitize cancer cells to DNA-damaging agents. However, it remains unclear which kinase is the most therapeutically relevant target, and whether multiple kinases might need to be targeted to achieve the best efficacy because of their overlapping substrate spectra and redundant functions. To clarify this issue, we established asynchronous cell cycle arrest models to investigate the therapeutic outcomes of silencing Chk1 and Chk2 in the presence of irradiation or cisplatin. Our results showed that Chk1-and Chk2-targeting small interference RNAs (siRNAs) demonstrated synergistic effects when both siRNAs were used simultaneously. Interestingly, Chk1 and Chk2 co-expression occurred in B90% of neoplastic tissues examined and showed no difference in neoplastic versus non-neoplastic tissues. Therefore, the selective targeting of Chk1 and Chk2 by oncolytic adenovirus mutants was chosen to treat resistant tumor xenograft mice, and the maximum antitumoral efficacy was achieved with the combined co-abrogation of Chk1 and Chk2 in the presence of low-dose cisplatin. This work deepens our understanding of novel strategies that target checkpoint pathways and contributes to the development of novel, potent and safe checkpoint abrogators.
INTRODUCTION DNA-damaging agents are among the most effective anticancer agents in clinical use and constitute the cornerstones of modern cancer treatment. However, their effectiveness largely depends on the function of surveillance systems, which are termed as cell cycle checkpoints. 1 Upon genotoxic challenge, these checkpoints work to initiate cell cycle arrest at different phases of the cell cycle to allow sufficient time for DNA repair, thereby promoting cell survival and, as a result, constituting a major mechanism of widespread tumor resistance to chemo-or radiotherapy.
Checkpoints that respond to DNA damage have been empirically defined at the G1, S and G2/M phases of the cell cycle. 2 Unlike normal cells with a full arsenal of checkpoint responses, tumor cells that are defective in some checkpoints must rely on the remaining checkpoints to survive. Therefore, cell cycle checkpoint abrogation could be an attractive approach to circumvent cancer resistance because of the expected induction of mitotic catastrophe and apoptosis in tumor cells while largely sparing normal cells. 3, 4 Checkpoint kinases 1 and 2 (Chk1 and Chk2) are two structurally unrelated but functionally similar protein serine/threonine kinases that have emerged as the major mediators of cell cycle modulation in response to DNA-damaging agents. Both kinases are known to relay checkpoint signals from the upstream signal-transducing kinases ataxia telangiectasia mutated and ataxia telangiectasia and RAD3 related to proximal substrates. 5 Although Chk1 is known to be activated by phosphorylation at Ser345 by ataxia telangiectasia and RAD3 related, the activation of Chk2 in checkpoint signaling is initiated by phosphorylation at Thr68 in an ataxia telangiectasia mutated-dependent manner. 6, 7 The inhibition of Chk1 and Chk2 by different approaches, for example, antisense oligodeoxynucleotides, small interference RNA (siRNA) or small molecule chemicals, was found to abrogate the S and G2/M checkpoints and potentiate the therapeutic efficacy of DNA-damaging agents, and thus has been proposed as adjuvant therapeutics to circumvent tumor resistance to anticancer drugs. [8] [9] [10] [11] A nonselective inhibitor, UCN-01, has undergone early clinical evaluations either alone or in combination with established cytotoxic agents. 12, 13 A series of new inhibitors, possibly even more specific than UCN-01, are in preclinical development. 14, 15 Nevertheless, it remains be fully elucidated which type of inhibitor, that is, against Chk1, Chk2 or both, will be more effective for clinical cancer therapy. Theoretically, the complementary actions of Chk1 and Chk2 that are specifically activated depending on the type and extent of DNA damage and the overlapping substrates Cdc25A/C of Chk1 and Chk2 may provide supportive evidence that the simultaneous inhibition of both Chk1 and Chk2 are necessary to fully abrogate the checkpoint, and hence achieve the best efficacy of potentiation. 7, 16 To clarify this issue, we investigated the therapeutic outcome of silencing Chk1 and Chk2 both singly and simultaneously, alone or in combination with irradiation or cisplatin treatment. Chk1/Chk2 siRNA significantly knocked down the expression of the Chk1/ Chk2 proteins yet caused little effect on apoptosis and the cell cycle in the absence of DNA-damaging agents. In the presence of DNA-damaging agents, Chk1-or Chk2 siRNA-enhanced irradiationor cisplatin-induced apoptosis and further demonstrated synergistic effects when these two siRNAs were used simultaneously. As the co-expression pattern of Chk1 and Chk2 occurred in B90% of the neoplastic tissues examined and exhibited no difference in cancerous versus non-cancerous tissues, we constructed novel oncolytic adenovirus mutants preferentially targeting Chk1 and Chk2 in cancer rather than in normal cells and demonstrated 1 Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China and potent antitumoral efficacy in the presence of low-dose cisplatin in vivo. Again, simultaneous targeting of Chk1 and Chk2 produced synergistic effects and achieved the best efficacy.
MATERIALS AND METHODS

Cell lines, viruses and reagents
The human cervical carcinoma cell lines HeLa and SiHa, human breast carcinoma cell line MCF-7, human endometrial carcinoma cell line HEC-1-B and human hepatic carcinoma cell line HepG2 were obtained from the American Type Culture Collection and grown in Dulbecco's modified Eagle medium with 10% fetal calf serum (FCS). The human ovarian cancer cell line A2780, human lung cancer cell line A549, human acute promyelocytic leukemia cell line HL-60 and human chronic myelogenous leukemia cell line K562 were grown in RPMI-1640 with 10% FCS. A human umbilical vein/ vascular endothelium cell line was obtained from American Type Culture Collection and grown in F-12K medium with 10% FCS. Primary leukemia cells were separated from the bone marrow of three cases of newly diagnosed primary acute myeloid leukemia according to standard protocols and cultured in RPMI-1640 with 10% FCS. All Adv5 mutants used in the present study were constructed in-house from the HEK-293 cell line following protocols detailed elsewhere. Ad5/dE1A with a deletion of amino acids 121-129 in E1A CR2 was previously constructed. 16 M2 or M3 was expressed from Adv5/dE1A via the replacement of the 6.7K/gp19K open reading frame in the E3 region by a fragment of reverse Chk1 cDNA (bases 853-250) or Chk2 cDNA (bases 1686-858). 17, 18 The virus mutant was constructed by homologous recombination in HEK-293 cells.
19 Cisplatin (DDP) was obtained from QiLu pharmaceutical company, Shandong, China. Dulbecco's modified Eagle medium, RPMI-1640, FCS and the Lipofectamine with Plus transfection kit were purchased from Invitrogen (Carlsbad, CA, USA). The annexin V/ propidium iodide (PI) apoptosis detection kit was purchased from BD Biosciences (San Jose, CA, USA). A purified mouse anti-cytochrome c antibody was purchased from BD Pharmingen (San Jose, CA, USA) and a rabbit anti-voltage-dependent anion-selective channel 1 (VDAC1) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-human Chk1 and Chk2 antibodies, cleaved caspase-3, and b-actin were purchased from Cell Signaling Technology (Danvers, MA, USA).
siRNA transfection and drug treatment
The sequences of an siRNA fragment against human Chk1 (5 0 -aactgaagaagcagtcgcagt-3 0 ), Chk2 (5 0 -aatgtgtgaatgacaactact-3 0 ) and a mismatched fragment (Si-con, 5
0 -aacaagtgaagcagtcgcagt-3 0 ) were synthesized according to sequences published elsewhere. 17, 18 For the transfection procedure, siRNA or Si-con was transfected into tumor cells using the Oligofectamine reagent (Invitrogen) according to the manufacturer's instructions. The DNA-damaging agent was added to the cells at 24 h after transfection.
Western blot analysis
The preparation of protein samples and western blotting were performed as described previously. 19 Cell cycle and apoptosis analysis Different cell groups were harvested with 0.25% trypsin, washed with phosphate-buffered saline (PBS) and separated into two portions. One portion was freshly prepared by centrifugation, and the cells were resuspended in 300 ml buffer and stained with annexin V and PI; the cells were sorted using a FACScan (BD Biosciences) and analyzed using Cell Fit software (San Jose, CA, USA). The other portion was fixed in 75% ice-cold ethanol overnight at À 20 1C. After washing in PBS, the cells were treated for 30 min at 37 1C with 50 mg ml À 1 PI and 1 mg ml À 1 RNase A. Subsequent analyses of cell cycle distribution and apoptosis were performed using CELLQuest software (BD Biosciences). Each experiment was repeated three times.
Analysis of cell cycle-specific apoptosis (annexin V and propidium iodide method) Cells were harvested with 0.25% trypsin, washed with PBS and resuspended in binding buffer. A 5-ml aliquot of fluorescein isothiocyanateannexin V was added to 100 ml of freshly collected cells suspended in binding buffer at a density of 10 6 cells per ml and incubated in the dark for 20 min. The sample was then resuspended in 1 ml of 1% methanol-free formaldehyde in binding buffer for 30 min on ice and rinsed twice. The sample was resuspended in 0.5 ml of PI solution containing 50 mg ml À 1 PI, 0.1% RNase A (Sigma, St Louis, MO, USA), 500 mg ml À 1 digitonin (Sigma), 10 mM PIPES (Sigma), 2 mM CaCl 2 and 0.1 M NaCl, placed at room temperature for 1 h in the dark, and analyzed by flow cytometry for the cell cycle specificity of apoptotic cells. Untreated cells served as the negative control.
Clinical specimens
The current study included specimens from 223 patients including 44 patients with primary endometrial carcinoma, 43 patients with primary cervical carcinoma, 39 patients with primary ovarian carcinoma and 33 patients with primary breast carcinoma who underwent surgery. None of the patients with malignant tumors received neoadjuvant chemotherapy or radiotherapy. Non-neoplastic tissues were also collected, including 11 patients with endometria in the proliferative phase, 10 patients with endometria in the secretory phase, 20 patients with non-neoplastic cervical tissues, 10 patients with non-neoplastic ovaries and 13 patients with non-neoplastic breast tissues. The tissue samples were obtained and handled in accordance with a protocol approved by the Institutional Review Board for Human Research of the TongJi Hospital. The slides were evaluated and scored by two pathologists who were blinded to each other to prevent observer bias. Each data point represents the mean of the results from the two pathologists.
Immunohistochemistry
Immunohistochemistry was carried out on paraffin-embedded sections using standard reagents and protocols (Vector Laboratories, Burlingame, CA, USA). For a semiquantitative evaluation, an immunoreactivity-scoring system was applied. The intensity of staining was designated as either not existent (0), weak (1), moderate (2) or strong (3). The number of cells stained was scored as either 0-9% cells stained (0), 10-39% of cells stained (1), 40-69% of cells stained (2) or 470% of cells stained (3). The immunoreactivity scoring was calculated by the multiplication of these two variables; the scores can range from 0 to 9. We confirmed a 0 score as negative to calculate the positive rate. These data were analyzed as a continuum, and the objective was to use this semiquantitative method to assess differences between the non-neoplastic and neoplastic tissues. The percentage of immunoreactive cells was calculated by counting at least 1000 tumor cells at high magnification ( Â 400).
Mouse tumor model
Four-week-old female BALB/c nu/nu mice were purchased from the SLAC Laboratory Animal (Shanghai, China) and maintained in a laminar-flow cabinet under specific pathogen-free conditions. MDA-MB-231 tumor cells (1 Â 10 6 ) were implanted into the mammary fat pad of the mice. When the tumors had grown to B4-5 mm, a dose of 2 Â 10 8 plaque formation unit virus mutant was injected intravenously by the tail vein daily for five consecutive days (12 mice per group). Four days later, cisplatin at a dose of 0.75 mg kg À 1 per day was injected into the abdominal cavity for four consecutive days. The tumors were monitored twice weekly until the mice were killed at 70 days after the initiation of treatment or when the tumor volume was 41200 mm 3 . The lymph nodes (axillary, supraclavicular and paratracheal), lungs and livers were collected and subjected to pathologic evaluation by pathologists for evidence of metastases.
Statistical analysis
All the data are presented as the means±s.d. of at least triplicate experiments and were analyzed by a one-way analysis of variance followed by a Student-Newman-Keuls test. Differences at Po0.05 were considered significant. For the in vivo data, the cumulative probability of survival was determined by the Kaplan-Meier method and the significance of differences with the log-rank test. All P-values were two-sided, and values o0.05 were considered significant. SPSS v11.5 software (SPSS, CA, USA) was used for all the statistical procedures. To determine the responsive pattern of asynchronously grown cancer cells to DNA-damaging agents, nine cancer cell lines, such as HeLa, A2780, MCF-7, A2780, HepG2, SiHa, HEC-1-B, HL-60 and K562 cells, were treated by cisplatin or irradiation over a range of varied doses and analyzed for cell cycle profiles at different time points after the initiation of treatment. These cell lines exhibited the most profound cell cycle arrest after the exposure to irradiation or cisplatin because an activated checkpoint was evident by the excessive accumulation of cells at the G1, S and G2/M phases. For the subsequent experiment, we choose three types of cancer cells that varied in their tissues of origin and in their response to DNA damage: cervical cancer cell line HeLa with a mutant Rb and p53 inactivated by HPV E6; lung cancer cell line A2780 with a wild-type p53 and mutant Rb; and breast cancer cell line MCF-7 with a wild-type p53 and wild-type Rb. Activation of the G1 checkpoint became evident at 6 h after the exposure of unsynchronized MCF-7 cells to 6 Gy 60 Co irradiation and reached maximal arrest at 24 h (Figure 2a) . In contrast, activation of the S checkpoint was observed at the 12-h time point and reached a maximum at 24 h in a time-dependent fashion after the exposure of unsynchronized A2780 to 20 mM cisplatin (Figure 2b) . Activation of the G2/M checkpoint after the exposure of unsynchronized HeLa cells to 10 Gy 60 Co irradiation became apparent at the 6-h time point and reached a peak at 48 h in a time-dependent fashion (Figure 2c ). Very interestingly, the most profound cell cycle accumulation was always accompanied with a minor apoptotic response under this experimental condition, and the apparent apoptotic cells always appeared later than the maximum cell cycle arrest time point in all the cell lines tested. This finding indicates that the G1, S and G2/M checkpoints provide tumor cells with sufficient time to repair before cell cycle progression is recovered, and that the damaged cells eventually move toward apoptosis because of the expected induction of mitotic catastrophe (Figure 2 ).
RESULTS
Silencing
Chk1 and Chk2 siRNAs abrogate checkpoints, enhance apoptosis induced by DNA-damaging agents, and show synergistic effects when used in combination To determine whether Chk1 or Chk2 siRNAs, which have no apparent toxicity in the absence of DNA-damaging agents, can abrogate cell cycle arrest and sensitize cancer cells to apoptosis in the presence of DNA-damaging agents, we transfected cells with either 50 nM Chk1-or Chk2-specific siRNA and incubated for 24 h before subjecting the cells to irradiation or cisplatin. The floating and adherent cells were then harvested at the maximum cell cycle arrest time point mentioned above for each cell model for cytometry analyses. Although the Si-coninfected HeLa cells exhibited a typical G2/M arrest, the exposure to Chk1 or Chk2 siRNA but not Si-con completely abolished this G2/M arrest and enhanced apoptosis by 200% compared with the corresponding control siRNA (Po0.01) (Figures 3a-f) . This enhanced apoptosis could be detected by cleaved caspase-3 and the release of cytochrome c from the mitochondria (Figure 3c and  d) . Similar results were found with regard to induced S-phase arrest in A2780 cells treated with cisplatin and induced G1-phase arrest in MCF-7 cells treated with irradiation (data not shown). More interestingly, the combined use of Chk1 and Chk2 siRNAs produced synergistic effects compared with the treatment with Chk1-or Chk2-specific siRNA alone in all of the cell models tested (Po0.05).
To examine the basis for Chk1-or Chk2-specific siRNAenhanced apoptosis, the API method was used to analyze cell cycle-specific apoptosis in Chk1 or Chk2 siRNA-transfected MCF-7 Figure 2 . DNA-damaging agents induced G1, S and G2/M cell cycle arrest models by activating various checkpoints in asynchronous tumor cells. Unsynchronized tumor cells (MCF-7, A2780 and HeLa) were treated by cisplatin or irradiation at the indicated doses. At various time points, the cells were pelleted for cell cycle and apoptosis analyses. The arrested cells gave rise to a net increase in G1-phase in MCF-7 cells after irradiation (a), a net increase in S-phase in A2780 cells after cisplatin treatment (b), and a net increase in G2/M-phase in HeLa cells after irradiation (c); the respective apoptosis net increase is also shown. The right panel represents a typical result of G1-, S-or G2/M-phase arrest, as determined by flow cytometry in the three cell lines after DNA-damaging agent treatment. IR, irradiation.
Abrogation of Chk1 and Chk2 produces synergistic effects F Ye et al cells. Interestingly, the MCF-7 cells treated by irradiation alone underwent apoptosis preferentially in G1-phase, whereas those treated with irradiation plus Chk1-or Chk2-specific siRNA but not Si-con showed apoptosis in either G1, S or G2/M-phase, suggesting that the inhibition of endogenous Chk1 or Chk2 sensitized the MCF-7 cells by altering the executive machinery of apoptosis (Figure 3g ). To confirm our finding in primary cancer cells, we extended our analysis to three clinical specimens of primary acute myeloid leukemia cells and tested the effects of Chk1-or Chk2-specific siRNA knockdown. The irradiated leukemic cells exhibited a typical G1 accumulation. Treatment with either Chk1-or Chk2-specific siRNA for 24 h before 2 Gy irradiation led to at least a 200% increase in apoptosis. Again, combined Chk1 and Chk2 knockdown resulted in synergistic effects compared with treatment with Chk1-or Chk2-specific siRNA alone (Po0.05; Figure 3h ). Voltage-dependent anion-selective channel 1 (VDAC1) from total mitochondria was used as a control for equal protein loading. Combined Chk1 and Chk2 siRNAs showed synergistic effects by significantly enhanced apoptosis (*Po0.05) (e) and abrogated cell cycle arrest (f ) in HeLa cells. **Po0.01. (g) Although Si-con-transfected MCF-7 cells exposed to irradiation showed preferentially triggered G1-phase apoptosis, Chk1/2 siRNA-transfected MCF-7 cells showed either G1-, S-or G2/M-phase apoptosis. (h) Primary acute leukemia cells (PLCs) were isolated and tested for the effects of Chk1-or Chk2-specific siRNA. Combined Chk1-and Chk2 siRNAs showed synergistic effects in PLCs (Po0.05). IR, irradiation.
Expression of Chk1 and Chk2 proteins in primary cancer tissues versus non-neoplastic tissues of respective organs
To be an ideal target for cancer therapy, a molecule must be preferentially expressed in cancer cells rather than the normal cells of the respective organs. There is, however, only very limited information available on the expression of the Chk1 and Chk2 proteins in cancers versus non-neoplastic tissues of the respective organs. To provide a rationale for the potential combination of Chk1-and Chk2-targeting therapy, we further determined the expression of the Chk1 and Chk2 proteins in primary ovarian carcinoma, endometrial carcinoma, cervical cancer and breast cancer specimens and compared with the corresponding nonneoplastic tissue specimens of respective organs. The Chk1 protein was ubiquitously expressed in all specimens examined. Chk2-positive staining of the cytoplasm and nucleus was found in B90% of the neoplastic tissues examined (Figure 4a) . A semiquantitative immunoreactivity H-scoring system was used to compare the expression of the Chk1 and Chk2 proteins in primary cancer specimens versus corresponding non-neoplastic tissues of origin; the results are illustrated in Table 1 . Although Chk1 and Chk2 protein expression was found to be at similar levels in the cancer specimens in comparison with the non-neoplastic tissue specimens of respective organs, the distribution in normal tissues was slightly different (Figure 4b ). The positive staining of blood vessels and muscle was observed in sections of the Chk1 proteinexpressing tissues but not in the Chk2 protein-expressing tissues.
In normal cervical epithelium, the expression of the Chk2 protein was found in the total epithelium, but the positive staining of Chk1 was determined to become progressively weaker from the basement to the surface of the cervical epithelium. The coexpression pattern of Chk1 and Chk2 occurred in almost all of the tumor specimens with evidence of metastasis and B90% of the neoplastic tissues examined.
Selectively targeting Chk1 and Chk2 shows synergistic effects in vitro when used in combination The universal expression pattern of the Chk1 and Chk2 proteins in neoplastic and non-neoplastic tissues at least indicated that targeting Chk1 and Chk2 made sense in targeted therapy design, and also hinted that a novel approach was urgently needed to preferentially target Chk1 and Chk2 in cancer rather than in normal cells to achieve therapeutic windows. As described previously, M2 and M3 were generated from Adv5/dE1A, an adenoviral mutant with a deletion of amino acids 121-129 in E1A CR2, through the replacement of the E3 6.7K/gp19K by a fragment of reverse Chk1 cDNA (M2) or reverse Chk2 cDNA (M3). 19, 20 Both M2 and M3 have been demonstrated in our previous reports to exhibit potent efficacy in vitro and in vivo by virtue of combining oncolysis with efficient Chk1/Chk2 silencing. 19, 20 In the present study, we sought to determine whether the combined silencing of Chk1 and Chk2 could achieve synergistic effects. As shown in Figure 5a , although the apoptosis induced by DNA-damaging agent cisplatin in A2780 cells was apparently potentiated by M2 or M3 (Po0.01), the killing efficacy was still strikingly enhanced by the combination of M2 and M3 (Po0.05 compared with M2 or M3 alone). These data were further confirmed in MCF-7 and HeLa cells (Figure 5b ). Conversely, M2 or M3 did not significantly sensitize human umbilical vein endothelial cells to DNA-damaging agents featuring a good therapeutic window (Figure 5b ).
Combined silencing of Chk1 and Chk2 demonstrates superior antitumoral efficacy in vivo To further assess the chemosensitized effects of the combined silencing Chk1 and Chk2 in vivo, we compared the antitumoral potency of M2 and M3 in combination with cisplatin in MDA-MB-231, an orthotopic breast cancer model, which has been well characterized as having a high frequency of metastasis and resistance to treatment. The MDA-MB-231 breast cancer-bearing mouse model was established previously. 21 When the tumors had grown to B4-5 mm in size, the mice were injected intravenously with various adenoviral mutants followed by treatment with cisplatin. Although all the mice (12/12) treated with cisplatin plus PBS died before day 35 after treatment, M2 or M3 injection alone or in combination plus cisplatin improved survival. Either M2 or M3 was significantly superior to improving survival compared with Adv5/dE1A (P ¼ 0.045, 0.017; Figure 6a ). In accordance with the in vitro results, the combination of M2 and M3 further improved survival compared with M2 or M3 injection alone (P ¼ 0.0394, 0.0393; Figure 6a) . A higher number of CR was achieved following Abbreviations: Chk1, checkpoint kinase 1; Chk2, checkpoint kinase 2.
Abrogation of Chk1 and Chk2 produces synergistic effects F Ye et al M2-(4/12) or M3-(3/12) treatment alone or in combination (6/12) when compared with Adv5/dE1A (1/12) (Figure 6b ). All the mice treated with cisplatin plus PBS were found to have metastases within the lymph nodes at the time of killing, whereas only 1/12 mice treated with M2, 2/12 with M3 and 0/12 with the M2 and M3 combination showed this metastasis (Figure 6c ). Efficient infection of the primary tumor was detected by in situ hybridization staining for fiber mRNA after five doses of the systemic administration of M2 or M3 (data not shown). A consequent reduction in Chk1 or Chk2 protein was evident in the M2-, M3-or M2 plus M3-treated mice model (Figure 6d ).
DISCUSSION
Various reports using Chk1 pathway interference methods have already suggested the dominant role of Chk1 in the control of checkpoints in somatic cells. This hypothesis was substantially reaffirmed by our findings that using Chk1-specific siRNA inhibition was sufficient to abrogate DNA damage checkpoints.
However, to date, the role of Chk2 in DNA-damaging agent-induced apoptosis is controversial. Chk2 is conflictingly recognized as both a promoter and an inhibitor of apoptosis. Chk2 has been regarded as a tumor suppressor that enhances apoptosis by stabilizing p53. [22] [23] [24] However, Chk2 has been proven to provide a survival signal in tumor cells because the inhibition of Chk2 facilitates CPT-or doxorubicin-induced apoptosis. 25, 26 According to our results, Chk2 siRNA markedly enhanced irradiation-or cisplatin-induced apoptosis in various types of cancer cells, suggesting that Chk2 is likely a universal apoptosis inhibitor. It appears that the role of Chk2 varies with the cellular genetic background, form of damage and potency. We propose that Chk2 may circumvent its own tumor-suppressive functions by promoting survival in the current DNA damage models.
Given the evidence that Chk1 and Chk2 are both central mediators in the DNA damage response and have been shown to share some overlapping substrates and possess redundant functions such as controlling cell cycle progression, 27, 28 regulating DNA repair 29, 30 and coordinating cell survival and death; 31,32 the simultaneous modulation of their activity should be necessary to fully abrogate the checkpoint, and hence confer maximal efficacy of potentiation. The data presented here clearly show that simultaneously silencing Chk1 and Chk2 synergistically enhanced irradiation-or cisplatin-induced apoptosis and achieved maximal efficacy in vitro and in vivo. This overall strategy clearly benefits the development of novel small molecule inhibitors such as AZD7762, a highly specific ATP-competitive Chk1/2 inhibitor, which was found to avoid many of the problems associated with the relatively nonspecific Chk1 inhibitor UCN-01 in initial clinical trials. 33 Moreover, Chk1/Chk2 inhibitors may indeed have a place as a substantial therapeutic option, holding particularly great promise for cancers that are refractory to conventional treatment modalities.
It was noteworthy that asynchronized cells were chosen for examining the effects of Chk1/Chk2 abrogators. The present cell models are more clinically relevant compared with the checkpoints initiated by synchronizing agents. Synchronizing agents per se can affect the expression pattern of cell cycle-related proteins involved in apoptosis and hence give rise to artificial results. Furthermore, synchronized cell models cover only part of the cell cycle-responsive patterns to DNA-damaging agents and are not sufficient to mimic the real situations of tumor cells undergoing chemo-or radiotherapy in a clinical context. In clinical cancer treatment, DNA-damaging agents would activate heterogeneous patterns of checkpoint activation rather than a homogeneous G2/M checkpoint activation. Our present data show that tumor cells maintained the G1, S and G2/M checkpoints to some extent, and that silencing Chk1 or Chk2 abrogated G1-phase arrest in MCF-7 cells and primary acute myeloid leukemia cells as well as S-phase and G2/M-phase arrest, thus sensitizing tumor cells to DNA-damaging agents in all asynchronized checkpoint models.
The present study presents interesting data on the expression levels of the Chk1 and Chk2 proteins in tissues. Although the distribution of the Chk1 and Chk2 proteins in normal tissues varies somewhat, the co-expression pattern of Chk1 and Chk2 occurred in B90% of the neoplastic tissues examined and showed no difference in cancerous versus non-cancerous tissues. To be an ideal target for cancer therapy, a molecule must be preferentially expressed in cancer cells versus normal cells of respective organs. Niida et al. also proved that the combined loss of Chk1 and Chk2 caused the accumulation of cells with spontaneous DNA damage under unperturbed conditions, leading to genomic instability and then tumor development, and suggesting that the inhibition of Chk1 or Chk2 as an approach to cancer therapy should be undertaken with careful consideration. 34 Novel adenoviral mutants capable of silencing tumor-associated Chk1 or Chk2 enabled us to overcome the obstacles mentioned above, and further demonstrate that maximum antitumoral efficacy was achieved with the combined coabrogation of Chk1 and Chk2 in the presence of low-dose cisplatin in a refractory to conventional treatment cancer model. Our findings emphasize the importance of the Chk1 and Chk2 kinases functioning in concert to maintain checkpoints when the cells are under DNA-damaging conditions. Having demonstrated a valuable therapeutic strategy involving the co-abrogation of Chk1 and Chk2 in treatment-resistant cancer, this work deepens our understanding of novel strategies targeting checkpoint pathways and contributes to the development of novel, potent and safe checkpoint abrogators.
